Benda Pharmaceutical Jiangling Plant Awarded GMP Certificate For The Production Of Ribavrin

Benda Pharmaceutical, Inc., a China-based pharmaceutical company producing both Gendicine, a commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, recently announced that its subsidiary, Jiangling Benda Pharmaceutical Co., Ltd. ("Jiangling Benda"), has received the Good Manufacturing Practice ("GMP") certificate by the Chinese State Food and Drug Administration ("SFDA") authorizing the production of Ribavrin at its Jiangling Plant.

"We are very excited that our Jiangling plant has successfully obtained the GMP certificate. This certificate represents the endorsement of our quality control system and production facilities by the SFDA, and is a major step to launch and market our Ribavrin in the domestic market," stated Charles Wan, Chief Executive Officer of Benda Pharmaceutical.

Jiangling Benda plans to produce four types of Active Pharmaceutical Ingredients (APIs), including Ribavrin, Asarin, Levofloxacin Mesylate and Ribose. The production of the APIs, with the exception of Ribose, requires GMP certification. The Jiangling plant was closed for renovation in July 2004 to comply with GMP standards and was reopened in August 2007 for the production of Ribose. It currently has all of the production equipment in place, and the new facilities have been installed and tested for Ribavrin and Ribose.

Additional information regarding this certificate, issued on April 9, 2008, can be found on the SFDA website ( www.sfda.gov.cn ).

About Jiangling Benda
Jiangling Benda develops, manufactures and sells Active Pharmaceutical Ingredients ("APIs"), which are one of the two components of any capsules, tablets and fluids that are pharmaceutically active. An API is the substance in a drug that produces the desired medicinal effect. The "excipient" is the inert material that holds the API (such as gelatin or water). About 3.7 per cent of the APIs that Jiangling Benda produced in 2004 were used to produce some of the company's finished medicines. The remainder was sold in the market to unrelated parties. Jiangling Benda did not sell to related Benda companies in 2006 or 2007.

About Benda Pharmaceutical, Inc.
Benda Pharmaceutical, Inc. ( www.bendapharma.com ), a China-based pharmaceutical company, produces traditional Chinese and conventional medicines, as well as Gendicine, a commercialized gene therapy medicine for the treatment of cancer.

SOURCE: Benda Pharmaceutical, Inc.